Mon, 14 Apr 2025
The decision to stop developing danuglipron adds to a string of setbacks in the pharmaceutical giant's bid to win a slice of the booming market for GLP-1s.
>>
Terms of Use | Privacy Policy | Manage Cookies+ | Ad Choices | Accessibility & CC | About | Newsletters | Transcripts
Business News Top © 2024-2025